Special Issue

Recent Advances in Immune-Mediated Cerebellar Ataxias: Pathogenesis, Diagnostic Approaches, Therapies, and Future Challenges

Message from the Guest Editors

The clinical category of immune-mediated cerebellar ataxias (IMCAs) has been established after 3 decades of clinical and experimental research. IMCAs include diverse etiologies, including paraneoplastic cerebellar degeneration (PCD), post-infectious cerebellitis, gluten ataxia, and anti-GAD ataxia. Recent remarkable progress has clarified various characteristics of these etiologies and therapeutic strategies in terms of immunotherapies. Some patients whose clinical profiles do not match those of classic types are now gathered in a spectrum of primary autoimmune cerebellar ataxia (PACA). It is still unclear how immune tolerance is broken, leading to autoimmune insults of the cerebellum, and how cerebellar circuits are damaged by antibody- or cell-mediated mechanisms. Antibodies may specifically target the cerebellar circuitry and impair synaptic mechanisms (synaptopathies). The present Special Issue aims to illuminate what is solved and what is unsolved in clinical practice and pathomechanisms of IMCAs.

Guest Editors

Prof. Dr. Mario Ubaldo Manto
Fonds de la Recherche Scientifique - FNRS, Brussels, Belgium

Dr. Hiroshi Mitoma
Medical Education Promotion Center, Tokyo Medical University, Tokyo 160-0023, Japan

Deadline for manuscript submissions

closed (10 June 2022)

Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney
Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:
reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

MDPI